Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series

Published:October 25, 2021DOI:


      Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse side effect of antiresorptive agents. However, withdrawal of such agents in patients with osteoporosis may increase the risk of fracture. The treatment of MRONJ is challenging, and standard treatment guidelines have yet to be established. In this study, the aim was to find out whether adjuvant daily or weekly teriparatide (TPTD) injections were beneficial for exposed bony MRONJ lesions compared with standard conservative management. We also studied the complications and the patients’ response to TPTD therapy. We enrolled 27 patients (January 2012 - December 2016) with chronic and refractory MRONJ. There were four men and 23 women (85% female). Nine patients who did not select TPTD therapy for several reasons formed the non-TPTD group; the remaining 18 were randomly assigned to the daily (n=9) or weekly (n=9) groups. All patients in both groups continued standard conservative therapy in addition to their daily or weekly subcutaneous injection of TPTD (20 μg or 56.5 μg, respectively). We evaluated the complications of TPTD and its benefits. Three patients in the daily group did not complete the study, resulting in six patients in the daily group, nine in the weekly group, and nine in the non-TPTD group in the final analysis. The exposed bone was completely covered with normal mucosa in all patients in the TPTD groups, and the healing period was shorter than that in the non-TPTD group. No patient had complications of atypical fractures of the femoral head. Daily and weekly TPTD treatment resulted in a shortened treatment period compared with standard conservative therapy, with no increase in the rate of complications or worsening of osteoporosis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Marx R.E.
        Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
        J Oral Maxillofac Surg. 2003; 61: 1115-1117
        • Fliefel R.
        • Tröltzsch M.
        • Kühnisch J.
        • et al.
        Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review.
        Int J Oral Maxillofac Surg. 2015; 44: 568-585
        • Ruggiero S.L.
        • Dodson T.B.
        • Fantasia J.
        • et al.
        American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update.
        J Oral Maxillofac Surg. 2014; 72: 1938-1956
        • Cauley J.A.
        Defining ethnic and racial differences in osteoporosis and fragility fractures.
        Clin Orthop Relat Res. 2011; 469: 1891-1899
        • Haentjens P.
        • Magaziner J.
        • Colón-Emeric C.S.
        • et al.
        Meta-analysis: excess mortality after hip fracture among older women and men.
        Ann Intern Med. 2010; 152: 380-390
        • Jiang Y.
        • Zhao J.J.
        • Mitlak B.H.
        • et al.
        Recombinant human parathyroid hormone (1–34) (teriparatide) improves both cortical and cancellous bone structure.
        J Bone Miner Res. 2003; 18: 1932-1941
        • Rubin M.R.
        • Bilezikian J.P.
        The anabolic effects of parathyroid hormone therapy.
        Clin Geriatr Med. 2003; 19: 415-432
        • Harper R.P.
        • Fung E.
        Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1–34)].
        J Oral Maxillofac Surg. 2007; 65: 573-580
        • Yoshiga D.
        • Yamashita Y.
        • Nakamichi I.
        • et al.
        Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws.
        Osteoporos Int. 2013; 24: 2365-2369
        • Yao M.
        • Shimo T.
        • Ono Y.
        • et al.
        Successful treatment of osteonecrosis-induced fractured mandible with teriparatide therapy: a case report.
        Int J Surg Case Rep. 2016; 21: 151-153
        • Zandi M.
        • Dehghan A.
        • Amini P.
        • et al.
        Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw.
        Clin Oral Investig. 2019; 23: 3987-3993
        • Ersan N.
        • van Ruijven L.J.
        • Bronckers A.L.
        • et al.
        Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.
        Dentomaxillofac Radiol. 2014; 43: 20130144
        • Ma Y.L.
        • Bryant H.U.
        • Zeng Q.
        • et al.
        New bone formation with teriparatide human parathyroid hormone-(1–34) is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
        Endocrinology. 2003; 144: 2008-2015
        • Cheung A.
        • Seeman E.
        Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.
        N Engl J Med. 2010; 363: 2473-2474
        • McClung M.R.
        • San Martin J.
        • Miller P.D.
        • et al.
        Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
        Arch Intern Med. 2005; 165: 1762-1768
        • Chen P.
        • Satterwhite J.H.
        • Licata A.A.
        • et al.
        Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
        J Bone Miner Res. 2005; 20: 962-970
        • Lindsay R.
        • Cosman F.
        • Zhou H.
        • et al.
        A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.
        J Bone Miner Res. 2006; 21: 366-373
        • Ettinger B.
        • San Martin J.
        • Crans G.
        • et al.
        Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
        J Bone Miner Res. 2004; 19: 745-751
        • Cosman F.
        • Nieves J.W.
        • Dempster D.W.
        Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis.
        J Bone Miner Res. 2017; 32: 198-202
        • Ma Y.L.
        • Zeng Q.Q.
        • Chiang A.Y.
        • et al.
        Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
        Bone. 2014; 59: 139-147
        • Fujihara R.
        • Mashiba T.
        • Yoshitake S.
        • et al.
        Weekly teriparatide treatment increases vertebral body strength by improving cortical shell architecture in ovariectomized cynomolgus monkeys.
        Bone. 2019; 121: 80-88
        • Yoshitake S.
        • Mashiba T.
        • Saito M.
        • et al.
        Once-weekly teriparatide treatment prevents microdamage accumulation in the lumbar vertebral trabecular bone of ovariectomized cynomolgus monkeys.
        Calcif Tissue Int. 2019; 104: 402-410
        • Estilo C.L.
        • Fornier M.
        • Farooki A.
        • et al.
        Osteonecrosis of the jaw related to bevacizumab.
        J Clin Oncol. 2008; 26: 4037-4038
        • Dhillon R.S.
        • Xie C.
        • Tyler W.
        • et al.
        PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis.
        J Bone Miner Res. 2013; 28: 586-597
        • Wilde F.
        • Steinhoff K.
        • Frerich B.
        • et al.
        Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107: 412-419
        • Muratsu D.
        • Yoshiga D.
        • Taketomi T.
        • et al.
        Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages.
        PLoS One. 2013; 8: e67906
        • Tsurushima H.
        • Kokuryo S.
        • Sakaguchi O.
        • et al.
        Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats.
        Int J Oral Maxillofac Surg. 2013; 42: 1481-1487
        • Kaneko J.
        • Okinaga T.
        • Hikiji H.
        • et al.
        Zoledronic acid exacerbates inflammation through M1 macrophage polarization.
        Inflamm Regen. 2018; 38: 16
        • Yoshiga D.
        • Nakamichi I.
        • Yamashita Y.
        • et al.
        Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - prognostic factors in the treatment of BRONJ.
        J Clin Exp Dent. 2014; 6: e22-e28
        • Kaibuchi N.
        • Hoshi K.
        • Yamazaki A.
        • et al.
        The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: a 12-year retrospective study of 129 patients.
        Bone Rep. 2021; 14: 101072